Article Text

Extended report
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
  1. Gerd R Burmester1,
  2. Andrea Rubbert-Roth2,
  3. Alain Cantagrel3,
  4. Stephen Hall4,
  5. Piotr Leszczynski5,
  6. Daniel Feldman6,
  7. Madura J Rangaraj7,
  8. Georgia Roane8,
  9. Charles Ludivico9,
  10. Min Bao10,
  11. Lucy Rowell11,
  12. Claire Davies11,
  13. Eduardo F Mysler12
  1. 1Free University and Humboldt University of Berlin, Berlin, Germany
  2. 2Klinikum der Universität zu Köln, Köln, Germany
  3. 3Centre Hospitalier Universitaire de Toulouse, Toulouse, France
  4. 4Cabrini Medical Centre, Malvern, Australia
  5. 5Poznan Medical University, Poznan, Poland
  6. 6Universidade Federal de São Paulo, São Paulo, Brazil
  7. 7Arthritis & Diabetes Clinic, Inc, Monroe, Louisiana, USA
  8. 8Rheumatology Associates of South Carolina, Charleston, South Carolina, USA
  9. 9East Penn Rheumatology Associates, Bethlehem, Pennsylvania, USA
  10. 10Genentech Inc, South San Francisco, California, USA
  11. 11Roche Products Limited, Welwyn Garden City, UK
  12. 12Organizacion Medica de Investigación, Buenos Aires, Argentina
  1. Correspondence to Dr Gerd R Burmester, Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany; gerd.burmester{at}

Statistics from

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.